NSE · BPLPHARMA
Bharat Parenterals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹56 Cr with net profit ₹4 Cr — a 6.59% net margin, versus -2.31% the period before.
Shareholding
As of 2026-06-30
- Promoter67.2%
- Public31.31%
- FII0.11%
- DII1.37%
3,059 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.46× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #18 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,89,613 Cr | 84.98 | 22.53 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,021 Cr | 41.91 | 4.63 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹44,587 Cr | 39.29 | 9.84 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹27,723 Cr | 96.2 | 21.5 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,236 Cr | 31.92 | 6.3 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹20,296 Cr | 71.37 | 7.83 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹17,618 Cr | 26.79 | 4.51 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹15,752 Cr | 30.49 | 5.21 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,435 Cr | 53.99 | 6.21 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,371 Cr | 50.42 | 6.83 | 12.36% | 18.59% |
| Bharat Parenterals Ltd.(this company) | ₹1,065 Cr | — | 3.29 | -2.54% | -4.77% |
AI analysis
AI-generated · google/gemini-2.5-flashBharat Parenterals Limited is listed on the Indian markets with a market capitalization of Rs 975 Cr. The company reported a revenue of Rs 352 Cr, with a dividend yield of 7% and a book value of Rs 467.55. The promoter holding stands at 67.2037% as of June 30, 2026.
Positives
- +The company has a dividend yield of 7%.
- +The promoter holding is substantial at 67.2037% as of June 30, 2026.
- +There are no reported promoter share pledges.
Negatives
- −The company reported negative annual EPS of -66.64 for March 2025.
- −The profit margin is significantly negative at -237.1%.
- −Return on Equity (ROE) is negative at -254.1%.
- −Return on Capital Employed (ROCE) is negative at -1.8265%.
- −Net profit was negative at -12.6262 Cr for the year ending March 2025.
Financial Performance
For the fiscal year ending March 2025, Bharat Parenterals Limited recorded a revenue of Rs 352.0007 Cr. The company's net profit for this period was negative at Rs -12.6262 Cr, resulting in earnings per share (EPS) of Rs -66.64. The EBITDA was also negative at Rs -21.0007 Cr for the same period.
Profitability & Returns
Bharat Parenterals Limited's profitability metrics indicate challenges, with a negative profit margin of -237.1%. The Return on Equity (ROE) was -254.1%, and Return on Capital Employed (ROCE) stood at -1.8265%. The EPS for the fiscal year ending March 2025 was -66.64.
Balance Sheet
The company's debt-to-equity ratio is 0.64. As of the latest available data, the book value per share is Rs 467.55. The company's market capitalization stands at Rs 975 Cr.
Ownership & Pledges
Promoters held 67.2037% of the shares as of June 30, 2026. Public shareholding was 31.3137%, while institutional holdings, including DII and FII, were 1.3738% and 0.1088% respectively. There were no promoter share pledges reported.
Data as of — price: 2026-09-24 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.